These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2583 related articles for article (PubMed ID: 28416639)

  • 1. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
    Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
    Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
    Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
    Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?
    Tovey S; Dunne B; Witton CJ; Forsyth A; Cooke TG; Bartlett JM
    Clin Cancer Res; 2005 Jul; 11(13):4835-42. PubMed ID: 16000581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
    Falck AK; Fernö M; Bendahl PO; Rydén L
    World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
    Ba JL; Liu CG; Jin F
    Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
    Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
    Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
    Bartlett JM; Brookes CL; Robson T; van de Velde CJ; Billingham LJ; Campbell FM; Grant M; Hasenburg A; Hille ET; Kay C; Kieback DG; Putter H; Markopoulos C; Kranenbarg EM; Mallon EA; Dirix L; Seynaeve C; Rea D
    J Clin Oncol; 2011 Apr; 29(12):1531-8. PubMed ID: 21422407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
    Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
    Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. St. Gallen endocrine response classes predict recurrence rates over time.
    Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
    Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of TFF1 for adjuvant endocrine therapy in Chinese women with early ER positive breast cancer: comparing aromatase inhibitors with tamoxifen.
    Zhou L; Yan T; Jiang Y; Di G; Shen Z; Shao Z; Lu J
    Breast; 2011 Feb; 20(1):15-20. PubMed ID: 20619646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
    von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
    Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
    Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predictive of response to hormone therapy in breast cancer.
    Rastelli F; Crispino S
    Tumori; 2008; 94(3):370-83. PubMed ID: 18705406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
    Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
    Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 130.